ACHE and Alzheimer disease: In particular, compound <b>17d</b> showed a well-balanced inhibitory profile against AChE and BuChE (IC<sub>50</sub> = 0.080 ± 0.007 μM for AChE, IC<sub>50</sub> = 0.044 ± 0.004 μM for BuChE), self-induced Aβ aggregation (58.4% ± 2.1% at 20 μM), and MAO-B (IC<sub>50</sub> = 0.18 ± 0.01 μM), suggesting that <b>17d</b> might be an excellent multifunctional agent for AD treatment.